Table 5.
List of ongoing clinical trials including chemotherapy or Hypomethylating agents andFLT3i.
| ClinicalTrial Id. | Drug/Drugs Combination | Phase | Setting |
|---|---|---|---|
| NCT03836209 | Gilteritinib+CT vs. Midostaurin+CT | II | DE NOVO FLT3+ AML |
| NCT04240002 | Gilteritinib+CT | I–II | DE NOVO FLT3+ AML |
| NCT04027309 | Gilteritinib+CT vs. Midostaurin+CT | III | DE NOVO FLT3+ AML |
| NCT05024552 | Vyxeos+Gilteritinib | I | RR FLT3+ AML |
| NCT03735875 | Venetoclax+Quizartinib | I | RR FLT3+ AML |
| NCT03250338 | Crenolanib+CT vs. CT | III | RR FLT3+ AML |
| NCT04140487 | Aza+Venetoclax+Gilteritinib | I–II | RR FLT3+ AML |
| NCT04293562 | Vyxeos+/-Gilteritinib vs. SOC | III | DE NOVO FLT3 +/− AML |
| NCT04047641 | Quizartinib+CT | II | RR AML |
| NCT01892371 | Quizartinib + Azacitidine/LDAC | I–II | RR FLT3 +/− AML |
| NCT04687761 | Azacitidine/LDAC+Venetoclax+Quizartinib | I–II | DE NOVO AML (elderly) |